Sanofi Ventures announced a $625 million capital infusion, increasing its total assets under management to over $1.4 billion. This significant investment aims to back early-stage biotech startups developing novel therapies for autoimmune diseases, neurological disorders, and cancer. The funding bolsters Sanofi's commitment to accelerating innovation and supporting emerging companies advancing breakthrough therapeutics across diverse indications.